NSE · LALPATHLAB
Dr. Lal Path Labs Ltd.
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹764 Cr with net profit ₹166 Cr — a 21.7% net margin, versus 17.62% the period before.
Shareholding
As of 2026-06-30
- Promoter53.19%
- Public7.86%
- FII17.36%
- DII21.59%
1,11,037 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 1.49× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Healthcare · ranked #8 of 79 by market cap · medians across 49 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Apollo Hospitals Enter. Limited | ₹1,28,472 Cr | 242.67 | 13.55 | 20.48% | 7.7% |
| Max Healthcare Institute Ltd. | ₹1,08,166 Cr | 315.74 | 10.07 | 13.42% | 17.23% |
| Fortis Healthcare Ltd. | ₹71,876 Cr | 270.47 | 7.26 | 10.53% | 11.41% |
| Narayana Hrudayalaya Ltd. | ₹42,315 Cr | 187.89 | 9.34 | 17.76% | 10.2% |
| Aster DM Healthcare Ltd. | ₹42,227 Cr | 299.63 | 9.23 | 8.48% | 8.36% |
| Global Health Limited | ₹38,526 Cr | 267.33 | 9.72 | 14.05% | 12.62% |
| Krishna Institute of Medical Sciences Ltd. | ₹33,517 Cr | 135.03 | 8.94 | 10.74% | 6.18% |
| Dr. Lal Path Labs Ltd.(this company) | ₹31,558 Cr | 239.5 | 12.58 | 20.13% | 18.27% |
| Poly Medicure Ltd. | ₹17,015 Cr | 256.67 | 5.47 | 10.37% | 17.18% |
| Dr. Agarwal's Health Care Limited | ₹15,494 Cr | 391.04 | 7.65 | 6.58% | 6.4% |
AI analysis
AI-generated · google/gemini-2.5-flashDr. Lal Path Labs Ltd. reported annual revenue of Rs 2864.18 Cr with a revenue growth rate of 10.5%. The company's profit margin stands at 18.27% and it has an EPS of 31.14. The last recorded market capitalization was Rs 28386 Cr.
Positives
- +Revenue grew by 10.5% to Rs 2864.18 Cr.
- +The debt-to-equity ratio is low at 0.08, indicating minimal reliance on borrowed capital.
- +Return on Equity (ROE) is 20.13%, and Return on Capital Employed (ROCE) is 25.5578%.
- +The company maintains a profit margin of 18.27%.
Negatives
- −The Price-to-Earnings (PE) ratio is 215.43, which is comparatively high.
- −The dividend yield is 121, but this figure may be an anomaly or require further clarification.
- −The quarterly net profit declined from Rs 150.6 Cr in Sept 2025 to Rs 90.5 Cr in Dec 2025.
- −The number of shareholders decreased from 49636 in Sept 2017 to 28685 in Sept 2016 from the available history.
Financial Performance
For the financial year ending Mar 2026, Dr. Lal Path Labs Ltd. recorded a revenue of Rs 2864.18 Cr, marking a modest growth of 10.5%. The annual net profit for the same period was Rs 504.779 Cr. More recently, in Mar 2026, quarterly revenue was Rs 702.7 Cr with a net profit of Rs 131.3 Cr. This followed a quarterly net profit of Rs 90.5 Cr on revenue of Rs 659.8 Cr in Dec 2025.
Profitability & Returns
The company’s profit margin was 18.27% for the latest fiscal year. Dr. Lal Path Labs Ltd. demonstrated a Return on Equity (ROE) of 20.13% and a Return on Capital Employed (ROCE) of 25.5578%. The Earnings Per Share (EPS) for the last reported period was 31.14.
Balance Sheet
The debt-to-equity ratio for Dr. Lal Path Labs Ltd. was 0.08, indicating a low level of leverage. The book value per share stood at Rs 149.62. No information on current assets or liabilities is available in the provided data.
Ownership & Pledges
As of June 30, 2026, promoters held 53.1875% of the company's shares. Foreign Institutional Investors (FIIs) held 17.3565%, while Domestic Institutional Investors (DIIs) held 21.5942%. Public shareholding was recorded at 7.8618%. There are no promoter shares reported as pledged.
Regulatory & Surveillance
There is no information available indicating any surveillance measures or specific regulatory actions pertaining to Dr. Lal Path Labs Ltd.
Data as of — price: 2026-07-30 · financials: Jun 26 · shareholding: Jun 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.